AMAG Pharmaceuticals reviews Feraheme net product revenues of $13.1M for first-quarter 2010 AMAG Pharmaceuticals, Inc. , a biopharmaceutical organization focused on the advancement and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the medical diagnosis of cancer and coronary disease, reported unaudited consolidated monetary results for the 1st quarter ended March 31 today, 2010.6 million shares of common stock, with net proceeds to the Company of around $165.6 million. AMAG received a $60 million upfront payment and is usually eligible to receive up to $220 million in development and industrial milestones. Additionally, AMAG shall receive tiered, double-digit royalties predicated on net sales of Feraheme in the licensed territories.Thankfully, you won’t have to eat your rice chilly and gummy to keep its lower calorie articles. The scientists say reheating the rice at another time doesn’t alter the rice’s chemical composition. Additionally, the experts say rice cooked this way won’t only help a person maintain a trim waist; it may also result in a healthier gut, since the bacteria in the rice offers a potent energy source to the great bacteria in our body. These results were presented at the 249th National Meeting & Exposition of the American Chemical Society.